| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 15.3644 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 15.3644. The average price that 007390.KQ shares were previous bought at was KRW 21.4176. The current market price is -28.3% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 14,333 (USD $10) compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 29.5832 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 29.5832. The average price that 039200.KQ shares were previous bought at was KRW 21.0043. The current market price is 40.8% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 73,573 (USD $50) compared to the previous valuation of Oscotec Inc. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 123.185 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 123.185. The average price that 068270.KS shares were previous bought at was KRW 121.694. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 193,314 (USD $131) compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.5437 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.5437. The average price that 096530.KQ shares were previous bought at was KRW 17.6933. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in 096530.KQ has fallen by KRW 7,820 (USD $5) compared to the previous valuation of Seegene, Inc. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.65883 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.65883. The average price that 13.HK shares were previous bought at was HKD 3.01399. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 1,782 (USD $229) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.8795 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.01883 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.01883. The average price that 1877.HK shares were previous bought at was HKD 2.51798. The current market price is 19.9% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 9,123 (USD $1,173) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1159.07 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1159.07. The average price that 207940.KS shares were previous bought at was KRW 760.081. The current market price is 52.5% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 74,337 (USD $50) compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.05851 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.05851. The average price that 2162.HK shares were previous bought at was HKD 5.35965. The current market price is 31.7% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 5,539 (USD $712) compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.6794 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.6794. The average price that 2252.HK shares were previous bought at was HKD 3.16268. The current market price is -15.3% lower than average price they were purchased at. The value of the holding in 2252.HK has fallen by HKD 23,175 (USD $2,979) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 84.1673 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 84.1673. The average price that 237690.KQ shares were previous bought at was KRW 55.5458. The current market price is 51.5% higher than average price they were purchased at. The value of the holding in 237690.KQ has fallen by KRW 9,445 (USD $6) compared to the previous valuation of ST Pharm Co.,Ltd. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 126.015 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 126.015. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 213.6% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 30,519 (USD $21) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 34.1656 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 34.1656. The average price that 302440.KS shares were previous bought at was KRW 36.2275. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 9,259 (USD $6) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 86.5932 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 86.5932. The average price that 326030.KS shares were previous bought at was KRW 77.4592. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 19,506 (USD $13) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 29.0778 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 29.0778. The average price that 328130.KQ shares were previous bought at was KRW 36.3011. The current market price is -19.9% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 17,740 (USD $12) compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.55313 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.55313. The average price that 3933.HK shares were previous bought at was HKD 1.67688. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 20,244 (USD $2,602) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.1259 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.1259. The average price that 4523.T shares were previous bought at was JPY 28.5269. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 133,904 (USD $854) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.3654 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.3654. The average price that 4549.T shares were previous bought at was JPY 13.728. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 549 (USD $3) compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.5154 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.5154. The average price that 4587.T shares were previous bought at was JPY 11.127. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in 4587.T has increased by JPY 26,126 (USD $167) compared to the previous valuation of PeptiDream Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.1768 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.1768. The average price that 4887.T shares were previous bought at was JPY 13.195. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 30,999 (USD $198) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 4.99392 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 4.99392. The average price that 4974.T shares were previous bought at was JPY 5.75157. The current market price is -13.2% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 5,090 (USD $32) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.0934 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.0934. The average price that 6869.T shares were previous bought at was JPY 14.9756. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 125,624 (USD $801) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 31.5941 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 31.5941. The average price that 6951.T shares were previous bought at was JPY 33.0489. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 6,838 (USD $44) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.1989 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.1989. The average price that 7575.T shares were previous bought at was JPY 10.1423. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 6,139 (USD $39) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.6296 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.6296. The average price that 7701.T shares were previous bought at was JPY 26.4723. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 179,280 (USD $1,143) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.9686 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.9686. The average price that 7747.T shares were previous bought at was JPY 16.8906. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 44,555 (USD $284) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 9.94491 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 9.94491. The average price that 9995.HK shares were previous bought at was HKD 9.70899. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 27,299 (USD $3,509) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 138.36 | USD 0 | The current share valuation price of A based on adjusted close was USD 138.36. The average price that A shares were previous bought at was USD 122.269. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in A has fallen by USD 19,586 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 228.79 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 228.79. The average price that ABBV shares were previous bought at was USD 201.245. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 68,512 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.69 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.69. The average price that ABCL shares were previous bought at was USD 3.61385. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 8,272 compared to the previous valuation of Abcellera Biologics Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.54 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.54. The average price that ABT shares were previous bought at was USD 124.674. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 72,593 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 27.83 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 27.83. The average price that ACAD shares were previous bought at was USD 20.1364. The current market price is 38.2% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 34,323 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 65.51 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 65.51. The average price that ACLX shares were previous bought at was USD 64.8725. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 16,647 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.75 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.75. The average price that ADPT shares were previous bought at was USD 6.89362. The current market price is 143.0% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 120,175 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 28.49 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 28.49. The average price that ALKS shares were previous bought at was USD 30.7179. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 27,662 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 331.49 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 331.49. The average price that AMGN shares were previous bought at was USD 296.507. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 5,028 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.31 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.31. The average price that AMLX shares were previous bought at was USD 13.5196. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in AMLX has fallen by USD 16,786 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 50.04 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 50.04. The average price that ANAB shares were previous bought at was USD 23.8129. The current market price is 110.1% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 7,467 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.43002 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.43002. The average price that ARCT shares were previous bought at was USD 13.0207. The current market price is -50.6% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 4,153 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.18 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.18. The average price that ARVN shares were previous bought at was USD 11.3626. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in ARVN has fallen by USD 11,797 compared to the previous valuation of Arvinas Inc |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 24.44 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 24.44. The average price that ASTH shares were previous bought at was USD 26.5685. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in ASTH has increased by USD 20,765 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 40.54 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 40.54. The average price that ATRC shares were previous bought at was USD 33.402. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 65,662 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.21 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.21. The average price that AUPH shares were previous bought at was USD 11.2153. The current market price is 44.5% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 15,881 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AXGN - Axogen Inc | HOLD | 0 @ USD 32.84 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 32.84. The average price that AXGN shares were previous bought at was USD 18.047. The current market price is 82.0% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 5,262 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 154.19 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 154.19. The average price that AXSM shares were previous bought at was USD 116.831. The current market price is 32.0% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 23,434 compared to the previous valuation of Axsome Therapeutics Inc |
| BANB.SW - | HOLD | 0 @ CHF 75.2675 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 75.2675. The average price that BANB.SW shares were previous bought at was CHF 65.0923. The current market price is 15.6% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 11,232 (USD $14,192) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 29.8654 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 29.8654. The average price that BAVA.CO shares were previous bought at was DKK 25.4205. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in BAVA.CO has fallen by DKK 14,845 (USD $2,338) compared to the previous valuation of |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.53 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.53. The average price that BCRX shares were previous bought at was USD 7.74854. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 20,598 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 27.77 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 27.77. The average price that BEAM shares were previous bought at was USD 18.6816. The current market price is 48.6% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 18,326 compared to the previous valuation of Beam Therapeutics Inc |
| BIIB - Biogen Inc | HOLD | 0 @ USD 174.82 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 174.82. The average price that BIIB shares were previous bought at was USD 130.477. The current market price is 34.0% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 13,067 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 129.054 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 129.054. The average price that BIM.PA shares were previous bought at was EUR 121.406. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 81,894 (USD $96,356) compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 301.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 301.03. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 97,815 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 301.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 301.03. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 97,815 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 34.8699 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 34.8699. The average price that BIOA-B.ST shares were previous bought at was SEK 29.997. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 19,627 (USD $2,127) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 25.46 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 25.46. The average price that BLFS shares were previous bought at was USD 25.7305. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 561 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 54.28 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 54.28. The average price that BMY shares were previous bought at was USD 53.3317. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in BMY has fallen by USD 112,186 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.09. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 50,509 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.09. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 50,509 compared to the previous valuation of MULSTRXSSXIMETFP |
| CDNA - Caredx Inc | HOLD | 0 @ USD 20.02 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 20.02. The average price that CDNA shares were previous bought at was USD 19.212. The current market price is 4.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Caredx Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 8.97 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.97. The average price that CERT shares were previous bought at was USD 10.4074. The current market price is -13.8% lower than average price they were purchased at. The value of the holding in CERT has fallen by USD 19,564 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 40.05 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 40.05. The average price that CGON shares were previous bought at was USD 41.6925. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in CGON has fallen by USD 2,227 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CHEMM.CO - | HOLD | 0 @ DKK 107.749 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 107.749. The average price that CHEMM.CO shares were previous bought at was DKK 78.2284. The current market price is 37.7% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 28,875 (USD $4,548) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 24.23 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 24.23. The average price that CPRX shares were previous bought at was USD 22.4325. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 11,814 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 202.87 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 202.87. The average price that CRL shares were previous bought at was USD 165.907. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in CRL has fallen by USD 8,848 compared to the previous valuation of Creightons Plc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 68.04 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 68.04. The average price that CRVL shares were previous bought at was USD 111.522. The current market price is -39.0% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 15,633 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 40.2 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 40.2. The average price that CSTL shares were previous bought at was USD 21.3129. The current market price is 88.6% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 41,187 compared to the previous valuation of Castle Biosciences Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.04 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.04. The average price that CTKB shares were previous bought at was USD 5.7145. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 9,430 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.63 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.63. The average price that DAWN shares were previous bought at was USD 8.3429. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 5,479 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.83. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 205,319 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.83. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 205,319 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 78.4451 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 78.4451. The average price that DIA.MI shares were previous bought at was EUR 54.1257. The current market price is 44.9% higher than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 23,267 (USD $27,376) compared to the previous valuation of DiaSorin SpA |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.13 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.13. The average price that DVAX shares were previous bought at was USD 12.6313. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 4,251 compared to the previous valuation of Dynavax Technologies Corporation |
| DXCM - DexCom Inc | HOLD | 0 @ USD 66.86 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 66.86. The average price that DXCM shares were previous bought at was USD 78.8148. The current market price is -15.2% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 99,139 compared to the previous valuation of DexCom Inc |
| DYVOX.ST - | HOLD | 0 @ SEK 11.293 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 11.293. The average price that DYVOX.ST shares were previous bought at was SEK 6.29712. The current market price is 79.3% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 26,335 (USD $2,854) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.1202 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.1202. The average price that EKTA-B.ST shares were previous bought at was SEK 5.63298. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 17,528 (USD $1,899) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 11.92 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 11.92. The average price that EMBC shares were previous bought at was USD 13.0183. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 2,757 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 17.6272 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 17.6272. The average price that EUZ.DE shares were previous bought at was EUR 18.7965. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in EUZ.DE has increased by EUR 22,126 (USD $26,033) compared to the previous valuation of Eckert & Ziegler SE however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.16 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.16. The average price that EVH shares were previous bought at was USD 9.55347. The current market price is -56.5% lower than average price they were purchased at. The value of the holding in EVH has increased by USD 17,756 compared to the previous valuation of Evolent Health Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.34437 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.34437. The average price that EVT.DE shares were previous bought at was EUR 6.56761. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 35,347 (USD $41,589) compared to the previous valuation of Evotec SE however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.23 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.23. The average price that EW shares were previous bought at was USD 74.591. The current market price is 15.6% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 58,387 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.59 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.59. The average price that EXAS shares were previous bought at was USD 62.0439. The current market price is 63.7% higher than average price they were purchased at. The value of the holding in EXAS has fallen by USD 52,053 compared to the previous valuation of EXACT Sciences Corporation |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 46.61 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 46.61. The average price that EXEL shares were previous bought at was USD 38.1215. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 137,413 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 17.91 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 17.91. The average price that FTRE shares were previous bought at was USD 10.5322. The current market price is 70.0% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 24,358 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 102.5 | USD 0 | The current share valuation price of GH based on adjusted close was USD 102.5. The average price that GH shares were previous bought at was USD 54.9629. The current market price is 86.5% higher than average price they were purchased at. The value of the holding in GH has increased by USD 172,411 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 125.19 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 125.19. The average price that GILD shares were previous bought at was USD 107.342. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 138,025 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 32.8051 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 32.8051. The average price that GLPG.AS shares were previous bought at was EUR 29.0814. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 679 (USD $799) compared to the previous valuation of Galapagos NV |
| GMAB.CO - | HOLD | 0 @ DKK 334.676 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 334.676. The average price that GMAB.CO shares were previous bought at was DKK 222.447. The current market price is 50.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 489,606 (USD $77,121) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.4658 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.4658. The average price that GSK.L shares were previous bought at was GBP 19.3589. The current market price is 26.4% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 81,927 (USD $110,355) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.36 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.36. The average price that HALO shares were previous bought at was USD 60.3305. The current market price is 13.3% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 29,566 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.77865 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.77865. The average price that HLUN-B.CO shares were previous bought at was DKK 6.0023. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 2,328 (USD $367) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.87 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.87. The average price that HOLX shares were previous bought at was USD 66.2934. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 9,059 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 38.44 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 38.44. The average price that HRMY shares were previous bought at was USD 32.6637. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 22,123 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 12.59 | USD 0 | The current share valuation price of IART based on adjusted close was USD 12.59. The average price that IART shares were previous bought at was USD 20.1099. The current market price is -37.4% lower than average price they were purchased at. The value of the holding in IART has increased by USD 1,610 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.1 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.1. The average price that IBRX shares were previous bought at was USD 2.81966. The current market price is -25.5% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 46,675 compared to the previous valuation of Immunitybio Inc |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.41 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.41. The average price that IDYA shares were previous bought at was USD 23.8167. The current market price is 48.7% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 9,524 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 136.19 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 136.19. The average price that ILMN shares were previous bought at was USD 95.299. The current market price is 42.9% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 236,438 compared to the previous valuation of Illumina Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.82 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.82. The average price that IOVA shares were previous bought at was USD 2.41138. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in IOVA has increased by USD 13,276 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 140.593 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 140.593. The average price that IPN.PA shares were previous bought at was EUR 120.641. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 5,962 (USD $7,015) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 225.15 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 225.15. The average price that IQV shares were previous bought at was USD 162.435. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 72,026 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 577.34 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 577.34. The average price that ISRG shares were previous bought at was USD 536.021. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 69,366 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.12 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.12. The average price that JANX shares were previous bought at was USD 24.7281. The current market price is -42.9% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 2,061 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 205.78 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 205.78. The average price that JNJ shares were previous bought at was USD 170.984. The current market price is 20.4% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 145,219 compared to the previous valuation of Johnson & Johnson |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.52 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.52. The average price that KNSA shares were previous bought at was USD 40.3374. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 51,999 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.79 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.79. The average price that KURA shares were previous bought at was USD 10.711. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 44,988 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.495 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.495. The average price that LAB shares were previous bought at was USD 1.39779. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in LAB has fallen by USD 76,646 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 197.39 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 197.39. The average price that LGND shares were previous bought at was USD 126.392. The current market price is 56.2% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 13,222 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 63.25 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 63.25. The average price that LIVN shares were previous bought at was USD 46.485. The current market price is 36.1% higher than average price they were purchased at. The value of the holding in LIVN has increased by USD 12,890 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 66.53 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 66.53. The average price that LNTH shares were previous bought at was USD 76.9588. The current market price is -13.6% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 123,089 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 674.812 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 674.812. The average price that LONN.SW shares were previous bought at was CHF 640.611. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 81,946 (USD $103,542) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 97.47 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 97.47. The average price that MDT shares were previous bought at was USD 90.2193. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 40,253 compared to the previous valuation of Medtronic PLC |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 569.7 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 569.7. The average price that MEDP shares were previous bought at was USD 382.527. The current market price is 48.9% higher than average price they were purchased at. The value of the holding in MEDP has fallen by USD 52,713 compared to the previous valuation of Medpace Holdings Inc |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 87.09 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 87.09. The average price that MMS shares were previous bought at was USD 75.2803. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 78,839 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 105.04 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.04. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 30.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 58,031 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 105.04 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.04. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 30.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 58,031 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 32.29 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 32.29. The average price that MRNA shares were previous bought at was USD 25.9653. The current market price is 24.4% higher than average price they were purchased at. The value of the holding in MRNA has fallen by USD 1,210,612 compared to the previous valuation of Moderna Inc |
| MRUS - Merus BV | HOLD | 0 @ USD 96.9 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.9. The average price that MRUS shares were previous bought at was USD 56.564. The current market price is 71.3% higher than average price they were purchased at. The value of the holding in MRUS has fallen by USD 3,872 compared to the previous valuation of Merus BV |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.29 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.29. The average price that MRVI shares were previous bought at was USD 2.97559. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 32,775 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.56 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.56. The average price that MYGN shares were previous bought at was USD 8.64702. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 21,764 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 147.28 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 147.28. The average price that NBIX shares were previous bought at was USD 127.74. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 29,560 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 7.15 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 7.15. The average price that NEOG shares were previous bought at was USD 9.99438. The current market price is -28.5% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 5,150 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 13.4767 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 13.4767. The average price that NEU.AX shares were previous bought at was AUD 8.87049. The current market price is 51.9% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 43,134 (USD $28,720) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 139.394 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 139.394. The average price that NOVN.SW shares were previous bought at was CHF 113.545. The current market price is 22.8% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 271,339 (USD $342,846) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 235.4 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 235.4. The average price that NTRA shares were previous bought at was USD 176.324. The current market price is 33.5% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 15,180 compared to the previous valuation of Natera Inc |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 9.34 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 9.34. The average price that NUVB shares were previous bought at was USD 6.64051. The current market price is 40.7% higher than average price they were purchased at. The value of the holding in NUVB has fallen by USD 58,269 compared to the previous valuation of Nuvation Bio Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.8 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.8. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 16,258 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.8 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.8. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 16,258 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.27 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.27. The average price that NVCR shares were previous bought at was USD 16.4121. The current market price is -19.1% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 21,390 compared to the previous valuation of Novocure Ltd |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.74611 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.74611. The average price that ONT.L shares were previous bought at was GBP 1.72772. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 3,501 (USD $4,716) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.82 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.82. The average price that PACB shares were previous bought at was USD 1.37661. The current market price is 32.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.88 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.88. The average price that PFE shares were previous bought at was USD 24.3485. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 200,341 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.69678 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.69678. The average price that PHARM.AS shares were previous bought at was EUR 0.896789. The current market price is 89.2% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 22,145 (USD $26,056) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 89.1368 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 89.1368. The average price that PHM.MC shares were previous bought at was EUR 87.1976. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 5,284 (USD $6,217) compared to the previous valuation of Pharma Mar SA |
| PME.AX - | HOLD | 0 @ AUD 155.357 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 155.357. The average price that PME.AX shares were previous bought at was AUD 165.183. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 496,858 (USD $330,828) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 285.5 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 285.5. The average price that PODD shares were previous bought at was USD 282.956. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in PODD has fallen by USD 299,761 compared to the previous valuation of Insulet Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 275.73 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 275.73. The average price that PRAX shares were previous bought at was USD 167.342. The current market price is 64.8% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 114,425 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 77.7 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 77.7. The average price that PTCT shares were previous bought at was USD 56.4444. The current market price is 37.7% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 113,553 compared to the previous valuation of PTC Therapeutics Inc |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 28.59 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 28.59. The average price that QDEL shares were previous bought at was USD 29.52. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 97,394 compared to the previous valuation of Quidel Corporation |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 22.71 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 22.71. The average price that RCUS shares were previous bought at was USD 9.14068. The current market price is 148.4% higher than average price they were purchased at. The value of the holding in RCUS has fallen by USD 44,806 compared to the previous valuation of Arcus Biosciences Inc |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 166.36 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 166.36. The average price that RGEN shares were previous bought at was USD 145.299. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 49,110 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 14.35 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 14.35. The average price that RGNX shares were previous bought at was USD 8.67354. The current market price is 65.4% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 32,928 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.31 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.31. The average price that RLAY shares were previous bought at was USD 5.08308. The current market price is 63.5% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 50,592 compared to the previous valuation of Relay Therapeutics Inc |
| RO.SW - | HOLD | 0 @ CHF 426.917 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 426.917. The average price that RO.SW shares were previous bought at was CHF 370.354. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 7,711 (USD $9,743) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 417.294 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 417.294. The average price that ROG.SW shares were previous bought at was CHF 324.411. The current market price is 28.6% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 301,029 (USD $380,361) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 97.58 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 97.58. The average price that RVTY shares were previous bought at was USD 100.003. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in RVTY has fallen by USD 26,869 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.36 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.36. The average price that RXRX shares were previous bought at was USD 5.14428. The current market price is -15.2% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 18,872 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 112.35 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 112.35. The average price that RYTM shares were previous bought at was USD 67.8137. The current market price is 65.7% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 36,753 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 18.81 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 18.81. The average price that SDGR shares were previous bought at was USD 22.5384. The current market price is -16.5% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 40,155 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 27.4429 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 27.4429. The average price that SECT-B.ST shares were previous bought at was SEK 28.0136. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 3,386 (USD $367) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 93.9419 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 93.9419. The average price that SFZN.SW shares were previous bought at was CHF 123.569. The current market price is -24.0% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 9,967 (USD $12,594) compared to the previous valuation of |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 19.33 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 19.33. The average price that SLP shares were previous bought at was USD 26.1345. The current market price is -26.0% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 180 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 22 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 22. The average price that SRPT shares were previous bought at was USD 45.0034. The current market price is -51.1% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 92,569 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 289.076 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 289.076. The average price that SRT3.DE shares were previous bought at was EUR 247.576. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 51,249 (USD $60,299) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.86 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.86. The average price that STOK shares were previous bought at was USD 12.0607. The current market price is 164.2% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 106,937 compared to the previous valuation of Stoke Therapeutics Inc |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 51.71 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 51.71. The average price that SUPN shares were previous bought at was USD 36.2354. The current market price is 42.7% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 14,008 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 59.25 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 59.25. The average price that TECH shares were previous bought at was USD 59.3169. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in TECH has increased by USD 54,542 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 164.208 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 164.208. The average price that TECN.SW shares were previous bought at was CHF 197.12. The current market price is -16.7% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 29,276 (USD $36,991) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 30.73 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 30.73. The average price that TGTX shares were previous bought at was USD 33.8235. The current market price is -9.1% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 67,092 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 579.94 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 579.94. The average price that TMO shares were previous bought at was USD 418.499. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 150,889 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 22.62 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 22.62. The average price that TNDM shares were previous bought at was USD 21.1386. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in TNDM has fallen by USD 52,631 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 33.84 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 33.84. The average price that TWST shares were previous bought at was USD 36.2456. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 82,438 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 16.5 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.5. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 57,696 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 16.5 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.5. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 57,696 compared to the previous valuation of Terex Corporation |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 283.542 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 283.542. The average price that UCB.BR shares were previous bought at was EUR 208.203. The current market price is 36.2% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 325,827 (USD $383,366) compared to the previous valuation of UCB SA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.92 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.92. The average price that VCYT shares were previous bought at was USD 34.3612. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 14,982 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.99 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.99. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 2,432 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.99 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.99. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 2,432 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.29552 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.29552. The average price that VLA.PA shares were previous bought at was EUR 2.91512. The current market price is 47.4% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 4,706 (USD $5,537) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 6.84 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 6.84. The average price that VNDA shares were previous bought at was USD 4.65578. The current market price is 46.9% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 12,781 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 32.11 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 32.11. The average price that VRDN shares were previous bought at was USD 30.1226. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in VRDN has fallen by USD 35,946 compared to the previous valuation of Viridian Therapeutics Inc |
| XVIVO.ST - | HOLD | 0 @ SEK 20.0268 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 20.0268. The average price that XVIVO.ST shares were previous bought at was SEK 40.1806. The current market price is -50.2% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 4,582 (USD $497) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.79 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.79. The average price that ZYME shares were previous bought at was USD 17.6935. The current market price is 51.4% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 50,752 compared to the previous valuation of Zymeworks Inc. Common Stock |